(19)
(11) EP 3 963 111 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
26.06.2024 Bulletin 2024/26

(45) Mention of the grant of the patent:
17.04.2024 Bulletin 2024/16

(21) Application number: 20729993.4

(22) Date of filing: 28.05.2020
(51) International Patent Classification (IPC): 
C12Q 1/6886(2018.01)
(52) Cooperative Patent Classification (CPC):
C12Q 2600/154; C12Q 1/6886
(86) International application number:
PCT/EP2020/064815
(87) International publication number:
WO 2020/239896 (03.12.2020 Gazette 2020/49)

(54)

DETECTION OF COLORECTAL CANCER

NACHWEIS VON KOLOREKTALKARZINOMEN

DÉTECTION DU CANCER COLORECTAL


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 31.05.2019 US 201916428865
31.12.2019 US 201962956059 P

(43) Date of publication of application:
09.03.2022 Bulletin 2022/10

(73) Proprietor: Universal Diagnostics, S.A.
41013 Sevilla (ES)

(72) Inventors:
  • BITENC, Marko
    1000 Ljubljana (SI)
  • KRUUSMAA, Kristi
    1000 Ljubljana (SI)
  • MARTINEZ-BAREA, Juan
    41013 Sevilla (ES)
  • HENSE, Christian
    41013 Sevilla (ES)
  • SOLA DE LOS SANTOS, Pol
    41013 Sevilla (ES)
  • CANAL NOGUER, Pol
    41013 Sevilla (ES)
  • CHERSICOLA, Marko
    1000 Ljubljana (SI)
  • KNAP, Primoz
    1000 Ljubljana (SI)

(74) Representative: Carlos Hernando, Borja 
Garrigues IP, S.L.P. Hermosilla, 3
28001 Madrid
28001 Madrid (ES)


(56) References cited: : 
EP-A2- 2 977 467
WO-A2-2012/167145
WO-A1-2015/153283
   
  • HAIDAN YAN ET AL: "Identifying CpG sites with different differential methylation frequencies in colorectal cancer tissues based on individualized differential methylation analysis", ONCOTARGET, vol. 8, no. 29, 18 July 2017 (2017-07-18), pages 47356-47364, XP055723769, DOI: 10.18632/oncotarget.17647
  • FELIX KORDOWSKI ET AL: "Aberrant DNA methylation of ADAMTS16 in colorectal and other epithelial cancers", BMC CANCER, vol. 18, no. 1, 6 August 2018 (2018-08-06) , XP055723762, DOI: 10.1186/s12885-018-4701-2
  • MICHAIL GALANOPOULOS ET AL: "Abnormal DNA methylation as a cell-free circulating DNA biomarker for colorectal cancer detection: A review of literature", WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, vol. 9, no. 4, 1 January 2017 (2017-01-01) , page 142, XP055723984, ISSN: 1948-5204, DOI: 10.4251/wjgo.v9.i4.142
  • K Kruusmaa ET AL: "MSRE-qPCR for analysis of gene specific methylation can be accurately used for detection and validation of colorectal cancer-specific patterns", 4Bio Summit, Rotterdam 2018, 1 January 2018 (2018-01-01), XP055723835, Retrieved from the Internet: URL:https://www.universaldx.com/wp-content /uploads/2017/05/4Bio-poster-November-2018 .pdf [retrieved on 2020-08-19]
  • A. A. MELNIKOV: "MSRE-PCR for analysis of gene-specific DNA methylation", NUCLEIC ACIDS RESEARCH, vol. 33, no. 10, 2 June 2005 (2005-06-02), pages e93-e93, XP055278893, ISSN: 0305-1048, DOI: 10.1093/nar/gni092
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).